Know Cancer

forgot password

An Open-Label Phase 2 Study of the Efficacy and Safety of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Phase 2
18 Years
Not Enrolling
Soft Tissue Sarcoma

Thank you

Trial Information

An Open-Label Phase 2 Study of the Efficacy and Safety of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Inclusion Criteria:

- At least 18 years of age

- Ability to understand the purposes and risks of the study and has signed a written
informed consent form approved by the investigator's IRB/Ethics Committee

- Pathologically confirmed diagnosis of soft tissue sarcoma

- Locally advanced unresectable or metastatic disease with no standard curative therapy
available that has progressed since the most recent therapy

- Measurable disease by RECIST criteria with at least one target lesion

- 1 or 2 prior chemotherapy/systemic therapy regimens for advanced disease

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2

- A minimum of 3 weeks between prior chemotherapy, radiation therapy, immunotherapy, or
other anti-tumor therapy and study entry

- Recovered from reversible toxicities of prior therapy

- Hemoglobin ≥ 9.0 g/dL, neutrophils ≥ 1,500/µL, platelets ≥ 100,000/µL

- Total bilirubin ≤ 1.5-fold ULN, AST/ALT ≤ 2.5-fold ULN (≤ 5-fold if liver metastases)

- Normal creatinine clearance (≥85 mL/min for men and ≥75 mL/min for women; calculated
by Cockcroft-Gault formula

- All women of childbearing potential must have a negative serum pregnancy test and all
subjects must agree to use effective means of contraception (surgical sterilization
or the use of barrier contraception with either a condom or diaphragm in conjunction
with spermicidal gel or an IUD) from entry into the study through 6 months after the
last dose

Exclusion Criteria:

- Soft tissue sarcoma of the following subtypes: gastrointestinal stromal tumor (GIST),
alveolar soft parts sarcoma, hemangiopericytoma and Kaposi's sarcoma

- Most recent relapse occurring during treatment with ifosfamide within 4 weeks of last

- Symptomatic brain or leptomeningeal metastases

- Active clinically significant infection requiring antibiotics

- Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or
4), particularly coronary artery disease, arrhythmias or conduction defects with risk
of cardiovascular instability, uncontrolled hypertension, clinically significant
pericardial effusion, cerebrovascular accident or congestive heart failure

- Previously treated malignancies, except for adequately treated non-melanoma skin
cancer, in situ cancer, or other cancer from which the subject has been disease-free
for at least 5 years

- Major surgery within 3 weeks of the start of study treatment, without complete

- Females who are pregnant or breast-feeding

- Participation in an investigational drug or device study within 21 days of study

- Concomitant disease or condition that could interfere with the conduct of the study,
or that in the opinion of the investigator would pose an unacceptable risk to the
subject in this study

- Unwillingness or inability to comply with the study protocol for any other reason

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Lee Cranmer, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Arizona


United States: Food and Drug Administration

Study ID:




Start Date:

March 2007

Completion Date:

October 2008

Related Keywords:

  • Soft Tissue Sarcoma
  • Sarcoma



Arizona Cancer CenterTucson, Arizona  85724
University of New Mexico Cancer Research and Treatment CenterAlbuquerque, New Mexico  87131
Stanford Cancer CenterStanford, California  94305-5824
St. Vincent's Comprehensive Cancer CenterNew York, New York  10011
H. Lee Moffitt Cancer CenterTampa, Florida  33612
Premiere Oncology of ArizonaScottsdale, Arizona  85260
Washington University School of Medicine, Division of OncologySt. Louis, Missouri  63110